1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
Physician Views: Will next-generation long-acting insulins prove compelling?

Physician Views: Will next-generation long-acting insulins prove compelling?

  • November 2014
  • ID: 2506828
  • Format: PDF
  • By Firstword Pharma

Summary






In the second of two diabetes-focused Physician Views polls being run by FirstWord Pharma PLUS this week (see also Physician Views: What opportunity for biosimilar basal insulin?), we are polling US and EU5-based endocrinologists to gauge their assessment of new long-acting insulins developed by Novo Nordisk (Tresiba), Sanofi (Toujeo) and Eli Lilly (Peglispro).

These newer products are poised to play a key role in how the multi-billion dollar basal insulin segment evolves over the next decade. They will dictate market share dynamics for their developers and should contribute to insulating the branded segment from loss of market share to biosimilar/generic versions of Sanofi's market-leading Lantus (expected to launch in the EU in 2015 and the US from 2016). This second issue appears particularly pertinent given the feedback we received earlier this week from endocrinologists, who appear very comfortable with the concept of prescribing biosimilar/generic Lantus (Physician Views Poll Results: What opportunity for biosimilar basal insulin?).

The significance of these newer products has also increased in light of Sanofi's recent disclosure that Lantus sales will be flat next year (due most likely to greater rebating with payers) and the potential leverage their availability will have on increased price compression in the market, alongside the subsequent launch of biosimilar/generic Lantus products. Concurrently, increasing efforts by payers to negotiate greater discounts could adversely impact the launch trajectories of these newer brands, argue some analysts, who cite only incremental improvement over currently available basal insulins.









How these products are differentiated from Lantus and Novo Nordisk's marketed Levemir franchise, and how they are differentiated from each other is at the crux of forecasting their commercial outlook and the questions we are asking as part of this Physician Views poll. Specifically we are asking US and EU5-based endocrinologists...


Based on your knowledge of clinical data for newer long-acting insulins (Sanofi's Toujeo, Novo Nordisk's Tresiba and Eli Lilly's Peglispro), how would you describe the level of improvement these products broadly provide over currently-available therapies?


Overall, do you think these newer long-acting insulins demonstrate sufficient efficacy (i.e. hypoglycaemia) and convenience benefits (i.e. reduced daily dosing) to warrant premium pricing versus Sanofi's Lantus?


Which of these newer long-acting insulins do you think offers the most compelling improvement over existing therapies?


What is the primary factor for you selecting that product?

Returning to the key theme in Q1 (how would you describe the level of improvement these products broadly provide over currently available therapies), what 'bar to entry' do you broadly expect newer branded long-acting insulins to raise for biosimilar Lantus? (US respondents assume that biosimilar Lantus is NOT rated as interchangeable)


Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.

ref:plp2014

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on